Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Other Non-Current Liabilities data on file, last reported at $3.5 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $3.5 million, down 69.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 69.57% YoY), and the FY2025 annual result was $4.0 million, down 65.22% from the prior year.
• Other Non-Current Liabilities declined to $3.5 million in Q1 2026 per PHAT's latest filing, from $4.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $11.5 million in Q4 2024 and troughed at $3.5 million in Q1 2026.
• A 5-year average of $8.6 million and a median of $7.5 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities soared 81.82% in 2022, then sank 69.57% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $7.5 million in 2022, then advanced by 29.33% to $9.7 million in 2023, then rose by 18.56% to $11.5 million in 2024, then plunged by 65.22% to $4.0 million in 2025, then fell by 12.5% to $3.5 million in 2026.
• Business Quant data shows PHAT's Other Non-Current Liabilities at $3.5 million in Q1 2026, $4.0 million in Q4 2025, and $11.5 million in Q3 2025.